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Abstract
The potential etiological role of early acetaminophen exposure on Autism Spectrum Conditions (ASC) and Attention-Deficit/
Hyperactivity Disorder (ADHD) is inconclusive. We aimed to study this association in a collaborative study of six European 
population-based birth/child cohorts. A total of 73,881 mother–child pairs were included in the study. Prenatal and postnatal 
(up to 18 months) acetaminophen exposure was assessed through maternal questionnaires or interviews. ASC and ADHD 
symptoms were assessed at 4–12 years of age using validated instruments. Children were classified as having borderline/
clinical symptoms using recommended cutoffs for each instrument. Hospital diagnoses were also available in one cohort. 
Analyses were adjusted for child and maternal characteristics along with indications for acetaminophen use. Adjusted cohort-
specific effect estimates were combined using random-effects meta-analysis. The proportion of children having borderline/
clinical symptoms ranged between 0.9 and 12.9% for ASC and between 1.2 and 12.2% for ADHD. Results indicated that 
children prenatally exposed to acetaminophen were 19% and 21% more likely to subsequently have borderline or clinical 
ASC (OR = 1.19, 95% CI 1.07–1.33) and ADHD symptoms (OR = 1.21, 95% CI 1.07–1.36) compared to non-exposed chil-
dren. Boys and girls showed higher odds for ASC and ADHD symptoms after prenatal exposure, though these associations 
were slightly stronger among boys. Postnatal exposure to acetaminophen was not associated with ASC or ADHD symptoms. 
These results replicate previous work and support providing clear information to pregnant women and their partners about 
potential long-term risks of acetaminophen use.
Keywords Acetaminophen · Paracetamol · Pregnancy · Autism · Attention-deficit/hyperactivity disorder
Introduction
Acetaminophen (or paracetamol) is used by 46–56% of preg-
nant women in developed countries [1–3]. Whilst acetami-
nophen is considered the safest analgesic/antipyretic for 
pregnant women and children, mounting evidence has linked 
prenatal acetaminophen exposure to worse cognitive perfor-
mance [4–6], more behavioural problems [1, 7, 8], Autism 
Spectrum Conditions (ASC) [6, 9] and Attention-Deficit/
Hyperactivity Disorder (ADHD) symptoms [1, 3, 6, 10]. 
Recently, detection of acetaminophen in meconium has asso-
ciated with increased odds of ADHD and altered frontopari-
etal connectivity at ages 9–10 years [11].
Two meta-analyses have investigated the link between 
prenatal acetaminophen use and ASC and ADHD symp-
toms [12, 13]. The first meta-analysis included seven 
cohort studies (N = 132,738) and reported risk increases of 
19% for ASC and 34% for ADHD [12]. The second meta-
analysis focused on ADHD, included eight cohort studies 
(N = 244,940) and concluded that exposed children had a 
25% increased risk of developing ADHD symptoms [13]. 
However, the methods and instruments used to assess the 
outcome in the studies included in the meta-analysis are 
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highly heterogeneous [14, 15]. Another source of hetero-
geneity among these studies regards the statistical approach 
and confounders included [14]. Furthermore, these studies 
did not address relevant unsolved questions regarding the 
link between early acetaminophen exposure and ASC and 
ADHD symptoms.
First, it is unclear whether girls or boys are differen-
tially affected by acetaminophen exposure. A recent study 
examining biomarkers of prenatal acetaminophen exposure 
among 996 mother–child pairs observed higher odds for 
ASC among boys and higher odds for ADHD among girls. 
[16] This is partially in agreement with a population-based 
study conducted in INfancia y Medio Ambiente (INMA) 
cohort representing 2644 mother–child pairs, where prena-
tal acetaminophen exposure was positively associated with 
ASC symptoms only among boys. [6] However, two studies 
including 64,322 mothers enrolled in the Danish National 
Birth Cohort (DNBC), reported slightly higher estimates 
among girls for ADHD and ASC without hyperkinetic symp-
toms [1, 9]. Second, the abovementioned studies on INMA 
cohort [6] and acetaminophen biomarkers [16] observed 
positive associations with both ASC and ADHD symp-
toms. This contrasts with the study conducted in the DNBC 
cohort where prenatal exposure was linked to ASC when 
accompanied by hyperkinetic symptoms [9]. Finally, another 
gap in research relates to postnatal exposure. An ecological 
study found positive correlations between indicators of both 
prenatal and postnatal acetaminophen exposures and ASC 
prevalence [17]. To our knowledge, postnatal associations 
have not been examined in prospective cohort studies.
In the current study, we aim to examine the association 
between early acetaminophen exposure and ADHD and ASC 
symptoms and hospital diagnosis. Furthermore, we also 
examined postnatal exposure and we present sex-stratified 
results. To reduce heterogeneity, we used a common set of 
confounders, the same statistical approach and harmonized 
the exposure and outcomes measurements across cohorts.
Methods
Sample
We included six European population-based birth 
cohorts: Avon Longitudinal Study of Parents and Children 
(ALSPAC), DNBC, Gene and Environment: Prospective 
Study on Infancy in Italy (GASPII), the Generation R Study, 
INMA (including four subcohorts), and the Mother–Child 
Cohort in Crete (RHEA) (Methods S1). Mother–child pairs 
were recruited from 1991 through 2008. A total of 73,881 
children with available data on either prenatal or postnatal 
exposure to acetaminophen and at least one outcome (ASC 
or ADHD symptoms) and main covariates were included 
(60.5% of the children recruited at baseline).
Informed consent was obtained from all participants in 
each cohort and ethical approval was obtained from the local 
authorized institutional review boards.
Exposure
Regarding prenatal acetaminophen exposure, mothers were 
interviewed two (INMA, RHEA), three (GASPII) or four 
(DNBC) times during pregnancy using standardized ques-
tionnaires. At each interview, mothers were asked if they had 
taken medications from the month before becoming preg-
nant (GASPII; INMA) or beginning of pregnancy (RHEA) 
through delivery. In ALSPAC and the Generation R Study, 
mothers completed questionnaires two (ALSPAC) or three 
(the Generation R Study) times during pregnancy report-
ing acetaminophen use from the month before becoming 
pregnant to gestational week 32 of pregnancy. In GASPII, 
mothers were interviewed at birth and provided retrospec-
tive information on acetaminophen use at each trimester. 
Mothers were classified as ever exposed if they reported 
having taken any dose of acetaminophen in the defined pre-
natal exposure period; otherwise they were classified as non-
exposed (More details in Table 1 and Supplemental Materi-
als (S) Methods S2).
Regarding postnatal acetaminophen exposure, mothers 
were interviewed (DNBC, GASP, RHEA) or completed 
questionnaires (INMA) about medication use in their chil-
dren one (RHEA) or two times (The Generation R Study, 
GASP, INMA, DNBC) in the first 18 months of life of the 
child. At each interview, mothers were asked if they had 
given any medication including acetaminophen, to their 
child. Children were classified as postnatally exposed to 
acetaminophen if they had taken any dose of acetaminophen 
at any time up to 18 months of life. Otherwise, they were 
considered non-exposed (Table 1, Methods S3).
Outcomes
ASC and ADHD symptoms were assessed using validated 
parent-reported questionnaires or linked hospital records. 
Autistic symptoms were assessed using the Development 
And Well-Being Assessment (DAWBA) [18] (ALSPAC), 
the Pervasive Developmental Problems (PDP) subscale of 
the Child Behaviour Checklist for Toddlers (CBCL1½–5) 
[19] (GASPII and The Generation R Study), the Child-
hood Autism Spectrum Test (CAST) [20] (INMA) and an 
ASC scale derived from the CBCL for 6–18 (CBCL6–18) 
[21] (RHEA). ADHD symptoms were assessed using the 
Development and Well-Being Assessment (DAWBA) [18] 
(ALSPAC); the Conner’s Parent Rating Scale Revised 
short form (CPRS-R:S) [22] (The Generation R Study), 
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the Hyperactivity/Inattention subscale of the Strengths and 
Difficulties Questionnaire (SDQ) [23] (DNBC), the Atten-
tion Deficit and Hyperactivity problems subscale of the 
CBCL1½-5 and CBCL6/18 (GASPII and RHEA), and the 
ADHD Criteria of DSM-IV (DSM-ADHD Questionnaire) 
[24] (INMA). Higher scores indicate more symptoms.
In addition to the SDQ-Hyperactivity/Inattention sub-
scale, in the DNBC cohort, diagnoses of ASC and ADHD 
from national hospital register were also available [1].
To harmonize the continuous scores on ASC and ADHD 
symptoms, we used questionnaire-specific validated cut-
offs to yield proxies for ASC and ADHD symptoms within 
the borderline/clinical range. Specifically, for the DSM-
ADHD Questionnaire scores, we applied established 
cut-offs consisting of 6 or more symptoms of inattention 
or hyperactivity to yield proxies for borderline/clinical 
ADHD symptoms [24]. For CBCL1½-5 and CBCL6/18 
scales, we used the recommended cut-off to classify chil-
dren with borderline/clinical symptoms corresponding to 
scores above 93rd percentile [25, 26]. Of note, since no 
specific cut-offs have been established for the ASC-CBCL 
scale [21], we applied the recommended cut-off abovemen-
tioned for the CBCL6/18 scales.25 The ADHD index of the 
CSRS-R:S has a cut-off for elevated T-scores (65–69) that 
we used to classify children as presenting borderline/clini-
cal symptoms (T-scores > 65) [22]. The DAWBA is based 
on diagnostic criteria (ICD-10 and DSM-IV) and focuses 
on anxiety disorders, depressive disorders, ADHD and 
conduct disorders. A clinical diagnostic rating is informed 
by triangulation of these three sources [27]. In the case of 
SDQ, abnormal scores in emotional problems and in peer 
problems or prosocial behaviour subscales were used to 
capture ASC borderline/clinical symptoms and abnormal 
scores in the SDQ hyperactivity/inattention and impact 
subscales were used to capture ADHD borderline/clinical 
symptoms [28]. Finally, for SCDC scores, the cut-off of 8 
to detect probable cases was applied to classify children 
as having borderline/clinical ASC symptoms [29]. Further 
details on outcomes measures and cut-offs applied can be 
found in Table 2 and Methods S4–S5. A summary of the 
Table 1  Assessment of exposures
a Number of children with data available on early acetaminophen exposure (prenatal or postnatal), at least one outcome (ASC or ADHD symp-
toms) and main covariates
b Number of children with data available for postnatal exposure, at lest one outcome and main covariates is 829
Cohort study Pregnancy period Na Prenatal Postnatal
Instrument N Exposed % Exposed Instrument N Exposed % Exposed
ALSPAC 1991–1992 6200 Maternal questionni-
are completed at 
18 and 32 weeks of 
pregnancy
2425 39.1 Maternal questionniare 
completed when chil-
dren were 12 months 
old
375 6.0
DNBC 1996–2002 61,430 Self-reported study 




and 30th week, and 
6-month postpartum)
34,584 56.3 Computer-assisted 
telephone inter-
views with moth-
ers when children 
were 6 months and 
18 months old
4735 7.7
GASPII 2003–2004 489 Interview with mothers 
at first, second and 
third trimesters of 
pregnancy
153 31.3 Interview with moths 
when children were 6 
and 15 months old
454 92.8
Generation R 2001–2005 3904 Maternal questionniare 
completed at 12, 
20 and 30 weeks of 
pregnancy
1150 29.5 Maternal questionniare 
completed when chil-
dren were 12 months 
old
2526 64.7
INMA 2004–2008 1513 Interview with mothers 
at weeks 12 and 32 of 
pregnancy
775 51.2 Maternal ques-
tionnaires when 
children were 6, 
14 or 18 months 
old (depending on 
subcohort)
750b 90.8 b
RHEA 2007–2008 345 Interview with mothers 
at weeks 12 and 30 of 
pregnancy
49 14.2 Interview with mothers 
when children were 
9 months old
306 88.7
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psychometric properties of the instruments used to assess 
the outcomes can be found in Table S1.
Covariates
Potential confounding variables were selected a priori prior-
itizing availability and consistency. Covariates were factors 
previously associated with ASC, ADHD and acetaminophen 
exposure, and include maternal and child characteristics. 
Maternal characteristics included age at delivery (years), 
education (low, medium, high), pre-pregnancy body-mass 
index (BMI), alcohol (yes/no), smoking (yes/no) and men-
tal health problems (yes/no) during pregnancy, age at birth 
(years) and parity (nulliparous, > 1 and > 2), maternal fever 
(yes/no) and infections (yes/no) during pregnancy. Mater-
nal education was not provided by the DNBC and analyses 
were adjusted by maternal socio-occupational status based 
on job titles instead. Child characteristics included sex, age 
at behavioural assessment (years), cold (yes/no) and respira-
tory infections (yes/no) in the first 2 years of life. Maternal 
characteristics were collected during pregnancy except for 
mental health in INMA, which was collected when children 
were around 5 years. Child characteristics were collected 
in the first 18 months of life. Two cohorts adjusted their 
analysis for cohort-specific covariates. Specifically, analy-
sis in Generation R Study were also adjusted by ethnicity 
(Dutch, non-Dutch/other western, non-western) and analysis 
in INMA were also adjusted by subcohort (INMA-Asturias, 
INMA-Gipuzkoa, INMA-Sabadell and INMA-Valencia).
Statistical analysis
All analyses were performed following the same protocol. 
We used logistic regression models to assess the association 
between prenatal and postnatal acetaminophen exposure and 
ASC or ADHD symptoms (as binary outcomes) within the 
borderline/clinical range. Separate models were conducted 
for prenatal and postnatal exposure, and for ASC and ADHD 
symptoms. Main models were adjusted for the abovemen-
tioned covariates and stratified by child sex.
Cohort-specific analyses were undertaken at each study 
centre and pooled using random-effects meta-analysis. Ran-
dom effects models, which account for unexplained hetero-
geneity, assume that the effect size varies across the stud-
ies because of real differences in the exposure effect and 
sampling variability [30]. Between-study heterogeneity was 
assessed using Cochran’s Q test and the I2 statistic.
Since the cohorts included herein differ in the length of 
follow-up, we performed meta-regression including mean 
age of the child at outcome assessment as moderator. These 
analyses allow us to examine potential changes in the associ-
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Sensitivity analyses included: (a) testing the associa-
tions with hospital diagnosis of ASC and ADHD available 
in the DNBC cohort, (b) testing the associations with ASC 
symptoms excluding ADHD cases, (c) meta-analyses leav-
ing out one cohort at a time to determine the influence of 
each cohort, and (d) additional adjustment for gestational 
age, birthweight (grams), maternal chronic diseases -except 
psychiatric diseases- (yes/no), maternal use of other drugs 
(yes/no) and maternal folic acid use (yes/no).
Analyses were performed using R 3.5.1 (https:// www.r- 
proje ct. org/). Logistic regression models to estimate odds 
ratio (OR) and 95% confidence interval (CI) were fitted 
using finalfit package (https:// final fit. org/ index. html). Meta-
analyses were conducted using metafor package [31].
Results
Across studies between 14 and 56% of mothers reported 
acetaminophen use in the prenatal period, with the RHEA 
cohort having the lowest proportion and DNBC the high-
est. A wider range of child postnatal acetaminophen expo-
sure was reported varying from 6% in ALSPAC to 92.8% in 
GASPII (Table 1).
The total number of children having ASC or ADHD 
symptoms within the borderline/clinical range was 1,481 
(2.1%) and 1,393 (2%), respectively (Table  2). Across 
cohorts, we observed large variations in the proportion of 
children presenting borderline/clinical symptoms with 0.9% 
and 12.9% presenting ASC symptoms and between 1.2 and 
12.2% presenting ADHD symptoms.
Table 3 shows the distributions of maternal and child 
characteristics.
Children with ASC symptoms within the borderline/clini-
cal range were more likely to be males and their mothers 
were more likely to be younger, have lower educational level 
and report alcohol consumption and mental health problems 
during pregnancy compared to children not in the borderline/
clinical range (Table S2). Children with ADHD symptoms 
within the borderline/clinical range were also more likely to 
be males and have a higher proportion of nulliparous moth-
ers, who smoked during pregnancy and experienced mental 
health problems during pregnancy compared to children not 
in the borderline/clinical range (Table S3).
Children prenatally exposed to acetaminophen were over-
all more likely to have older and non-nulliparous mothers 
with higher education levels and higher pre-pregnancy BMI 
who report alcohol consumption, smoking and mental health 
problems during pregnancy (Table S4). Children postnatally 
exposed to acetaminophen were more likely to have nullipa-
rous mothers, who have higher education levels and report 
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Prenatal acetaminophen exposure and ASC 
symptoms
Children prenatally exposed to acetaminophen were 19% 
more likely to subsequently have ASC symptoms within 
the borderline/clinical range than non-exposed children 
(OR = 1.19, 95% CI 1.07–1.33) (Fig. 1). Similar results 
were observed using hospital diagnosis in DNBC cohort 
(OR = 1.16, 95% CI 1.05–1.29) (Fig. S1). When stratifying 
by sex, prenatal acetaminophen was associated with ASC 
symptoms among boys (OR = 1.28, 95% CI 1.12, 1.46) and 
to a lesser extent among girls (OR = 1.06, 95% CI 0.82, 
1.36) (Table 4), though there was no statistical evidence 
of a difference between boys and girls (Pinteraction = 0.188). 
When using hospital diagnosis in DNBC, a similar effect 
size was observed in boys (OR = 1.14, 95% CI 1.00, 1.29) 
and girls (OR = 1.15, 95% CI 0.78, 1.71) (Table  S6). 
Excluding ADHD cases, prenatal acetaminophen expo-
sure was associated with ASC symptoms based on ques-
tionnaires in all cohorts (OR = 1.16, 95% CI 1.01, 1.43) 
(Table S7). Additional adjustment for other confound-
ers did not change the results meaningfully (Table S8). 
In leave-one-out analyses results, the association was 
attenuated but remained positive when omitting DNBC 
(OR = 1.12, 95% CI 0.96, 1.30 while no changes were 
observed when removing each of the other cohorts 
(Table S9).
Substantial between-study heterogeneity was only 
observed when examining this association among girls using 
hospital diagnosis in DNBC (I2 = 68.37%) (Table S6).
Meta-regression analyses showed that children’s age 
at outcome assessment did not modified the association 
between prenatal exposure to acetaminophen and ASC 
symptoms (P-value = 0.923).
Prenatal acetaminophen exposure and ADHD 
symptoms
The odds of developing ADHD symptoms within the bor-
derline/clinical range were 21% higher among children pre-
natally exposed to acetaminophen compared to non-exposed 
children (OR = 1.21, 95% CI 1.07–1.36) (Fig. 1). Prenatal 
acetaminophen use was associated with ADHD symptoms in 
boys (OR = 1.23, 95% CI 1.05, 1.44) and to a similar extent 
in girls (OR = 1.18, 95% CI 0.97, 1.44) (Pinteraction = 0.747) 
(Table 4). In sensitivity analysis, we observed positive 
associations using hospital diagnoses in DNBC (OR = 1.30, 
95% CI 1.14, 1.48) (Fig. S1) and consistent results in boys 
(OR = 1.31, 95% CI 1.15, 1.49) and girls (OR = 1.39, 95% 
CI 1.15, 1.68) (Table S6). Results were also similar with 
(A) (B)
(C) (D)
Fig. 1  Associations between early acetaminophen exposure and autis-
tic autism spectrum condition (ASC) (a, c) and attention-deficit and 
hyperactivity (ADHD) symptoms (b, d) within the borderline/clini-
cal range. Associations for prenatal (a, b) and postnatal (c, d) expo-
sure are shown. Symptoms were assessed using parent and teacher 
reported questionnaires in all cohorts. Odds Ratio (OR) and 95% 
confidence intervals (CI) by cohort and overall estimate obtained 
from random-effects meta-analysis. Models were adjusted for mater-
nal characteristics (education, age at delivery, pre-pregnancy body 
mass index, prenatal smoking, mental health during pregnancy, par-
ity and alcohol consumption, fever and infections during pregnancy) 
and child’s characteristics (sex, age at the behavioural assessment). 
Postnatal models were further adjusted by child’s cold or respiratory 
infections. Models on postnatal exposure and ADHD symptoms were 
not possible to conduct in RHEA cohort (limited sample size)
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additional adjustment for confounders (Table S8) or in leave-
one-out analysis (Table S9). There was no strong evidence 
of between-study heterogeneity (Fig. 1, Table 4, Fig. S2, 
Tables S6–S9).
Meta-regression analyses showed that children’s age 
at outcome assessment did not modified the association 
between prenatal exposure to acetaminophen and ADHD 
symptoms (P-value = 0.531).
Postnatal acetaminophen exposure and ASC 
symptoms
No association was found between postnatal acetaminophen 
exposure and ASC (OR = 0.99, 95% CI 0.73–1.35) (Fig. 1). 
Stratified results by sex were also close to the null for both 
boys and girls (Table 4, Table S4). Similar results were 
observed when using hospital diagnosis in DNBC (Fig. 1S). 
Results were also close to the null when excluding ADHD 
cases (Table S5) and with additional adjustment for other 
confounders (Table S6). There was evidence of between-
study study heterogeneity in main results (I2 = 48.4) (Fig. 1).
Meta-regression analyses showed that children’s age 
at outcome assessment did not modified the association 
between postnatal exposure to acetaminophen and ASC 
symptoms (P-value = 0.975).
Postnatal acetaminophen exposure and ADHD 
symptoms
No association was found between postnatal acetami-
nophen exposure and ADHD symptoms (OR = 0.97, 95% 
CI 0.75–1.25) (Fig. 1). Associations were also null when 
stratifying by sex (Table  4, Table  S6). Similar results 
were observed in sensitivity analysis using hospital diag-
nosis in DNBC (Fig. S1), with additional adjustment for 
other confounders (Table S8) and in leave-one-out analy-
sis (Table S10). There was no strong evidence of marked 
between-study heterogeneity (Fig.  1, Fig  S1, Table  4, 
Tables S6–S10).
Meta-regression analyses showed that children’s age 
at outcome assessment did not modified the association 
between postnatal exposure to acetaminophen and ADHD 
symptoms (P-value = 0.765).
Discussion
The results of our meta-analysis representing more than 
70,000 children of six European population-based birth/
child cohorts indicated that children prenatally exposed to 
acetaminophen were 19% and 21% more likely to subse-
quently have ASC and ADHD symptoms within the border-



































































































































































































































































































































































































































































































































































































































































































































 S. Alemany et al.
1 3
children. The association with ASC was attenuated after 
omitting the largest cohort but remained positive. When 
stratifying by sex, these associations were slightly stronger 
among boys compared to girls but positive associations with 
effect sizes of similar magnitude were observed in both 
strata, especially in the case of ADHD. Postnatal exposure 
to acetaminophen was not associated with either of the out-
come, thought there was evidence of between-study hetero-
geneity for the association with ASC symptoms.
The most consistent pattern of results was observed for 
the association between prenatal acetaminophen exposure 
and ADHD symptoms. The positive associations were 
observed in all the cohorts and of similar magnitude regard-
less of the cohort excluded in the leave-one-out analysis. 
This finding is in agreement with previous meta-analysis 
which reported likelihood increases of 25% and 34% for 
ADHD in relation to prenatal acetaminophen exposure 
[12, 13]. Our findings are consistent with previous single 
cohort studies conducted in ALSPAC [7], DNBC [1, 9] and 
INMA [6] cohorts, which were included in our meta-anal-
ysis. Despite the overlap of samples included, this agree-
ment supports the robustness of the findings since analytical 
strategies and outcome definitions were harmonized for the 
present meta-analysis.
The association between prenatal acetaminophen use and 
ASC symptoms was consistently positive even after omitting 
the largest cohort. Previous findings in DNBC only found 
this association in ASC cases with hyperactive symptoms 
[9], however, in our meta-analysis the association remained 
after excluding ADHD cases. Overall our findings provide 
support for the association between prenatal acetaminophen 
and ASC symptoms in line with a previous meta-analysis 
[12].
Associations between prenatal acetaminophen and ASC 
and ADHD symptoms were consistently positive for both 
boys and girls albeit slightly stronger among boys, with near 
identical odds ratios for hospital diagnosed cases in DNBC. 
Importantly, we found no evidence for statistical interac-
tion between child sex and prenatal acetaminophen exposure 
and either ASC or ADHD symptoms. This contrasts with 
previous findings in single cohort studies reporting sex dif-
ferences in the association between prenatal acetaminophen 
and ASC [6, 9, 16] and ADHD [8, 16]. Our findings suggest 
that differential sex effects of acetaminophen on ASC and 
ADHD symptoms, if any, are modest and may be dependent 
on the number of cases, outcome definition and assessment.
Associations between postnatal acetaminophen exposure 
and both ASC and ADHD symptoms were close to the null 
and different directions of associations around the null were 
observed across cohorts. Heterogeneity was high in the case 
of ASC, with about 50% of the variation in odds of ASC 
symptoms being explained by between study differences. 
The high prevalence of the exposure to acetaminophen when 
combining pre- and post-natal across studies made it impos-
sible to explore cumulative effects combining prenatal and 
postnatal exposures. Previous studies examining postnatal 
acetaminophen exposure have focused on ASC and results 
are mixed [17, 32, 33]. We do not find evidence supporting 
this association in either ASC or ADHD symptoms but fur-
ther research in larger samples is required.
The mechanisms proposed to underlie the adverse effects 
of early acetaminophen exposure on neurodevelopment 
include the stimulation of the endocannabinoid system, 
changes in brain-derived neurotrophic factor (BDNF) lev-
els, oxidative stress due to inflammation-induced immune 
activation, changes in neurotransmission and endocrine-
disruptive properties of acetaminophen [34, 35]. Acetami-
nophen exposure during periods equivalent to third trimester 
of pregnancy in humans but not later, induced behavioural 
and cognitive alterations in both male and female mice [36]. 
Other animal studies report findings that may be particularly 
interesting for ADHD. For instance, maternal exposure to 
acetaminophen was associated with lower levels of BDNF 
at the level of the striatum in an animal study conducted in 
male rats [37]. Furthermore, in male mice, acetaminophen 
treatment induced alterations in spatial learning, memory 
and dopamine metabolism [38]. Both the striatum region 
and dopamine are thought to play a pivotal role in ADHD 
[39–41].
The abovementioned findings provide biological plau-
sibility and coherence for the current findings. In this 
regard, other causal criteria supported by the current find-
ings include consistency and temporality [42]. Consistency 
is supported because we observed consistent results using 
a variety of populations and methods. Temporality is sup-
ported because the exposure precedes the onset of the symp-
toms assessed. Although we did not address dose-response 
relationship, previous studies have shown dose-response 
effects for both ASC and ADHD symptoms. [1, 6, 9]
Our findings need to be interpreted with caution given 
the limitations of our study. First, ASC and ADHD symp-
toms were assessed by different instruments in the cohorts. 
All instruments have been validated for the assessment of 
these symptoms, but the coverage may slightly differ among 
the instruments. To overcome this heterogeneity, we used 
instrument specific cut-offs to evaluate the presence or 
absence of borderline/clinical symptoms, a strategy that 
other meta-analysis analysing these outcomes have used [43, 
44]. Although cohorts differed in the prevalence of ASC and 
ADHD symptoms, associations were largely consistent. Of 
note, despite all instruments used herein are widely used in 
the field but it would be important to examine the psycho-
metric properties of the instruments used in each cohort to 
establish the specific objectivity of the outcomes. Second, 
confounding by indication cannot be completely ruled out 
although potential indications for acetaminophen use were 
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included as covariates (maternal fever or infections during 
pregnancy, maternal chronic illnesses, and child cold or 
infections in the first 18 months of life). Third, dose and 
frequency of use were not harmonized across cohorts and 
therefore, not analysed herein. Fourth, although results were 
adjusted by several lifestyles and health factors that have 
been shown to be associated with prenatal acetaminophen 
exposure [45], residual confounding by social class cannot 
be completed discarded. However, the consistent associa-
tions found across different sensitivity analysis including 
examining ASC and ADHD diagnosis in the largest cohort 
makes unlikely that the observed relationship between pre-
natal acetaminophen and ASC and ADHD symptoms is 
entirely explained by unmeasured confounding. Fifth, given 
the high rates of loss to follow-up in some of the included 
cohorts, we cannot discard selection bias in some of the 
cohorts. Nevertheless, loss to follow-up was low (< 2%) in 
the largest cohort included when using hospital diagnosis, 
which had broadly consistent findings compared to all the 
other cohorts together. Sixth, we have exposure information 
on postnatal acetaminophen use up to different ages in dif-
ferent cohorts and one regional cohort only collected medi-
cation in case of infection, which may have caused some 
exposure misclassification in that cohort. Finally, although 
information was prospectively collected, we cannot rule out 
information bias or misclassification of exposure.
Overall, despite the above limitations, the homogeneity 
of the findings among the different cohorts, the novel assess-
ment of postnatal acetaminophen exposure, and the use of an 
harmonized definition of exposure and outcome as well as 
of common statistical approaches overcomes the criticisms 
of previous meta-analysis [14, 15].
To conclude, our results support previous findings and 
address part of the weaknesses of previous meta-analyses. 
Considering all evidences on acetaminophen use and neu-
rodevelopment, we agree with previous recommendations 
indicating that while acetaminophen should not be sup-
pressed in pregnant women or children, it should be used 
only when necessary [46].
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